[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369220-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369220-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","exploring-mir-21-knock-out-using-crisprcas-as-a-treatment-for-lung-cancer","Exploring miR-21 Knock-Out Using CRISPR/Cas as a Treatment for Lung Cancer","","Lung cancer causes a high global burden of mortality, driven by late diagnosis, aggressive progression, and frequent resistance to chemotherapy. The study focuses on the PI3K/AKT pathway and on miR-21, a microRNA overexpressed in many cancers that promotes carcinogenic signaling by suppressing PTEN and PDCD4. Using CRISPR/Cas9, researchers aimed to eliminate miR-21 (miR-21 KO) in A549 lung cancer cells and evaluate effects on proliferation, migration, colony formation, target gene expression, and drug sensitivity across multiple chemotherapeutics.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/exploring-mir-21-knock-out-using-crisprcas-as-a-treatment-for-lung-cancer/369220/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/exploring-mir-21-knock-out-using-crisprcas-as-a-treatment-for-lung-cancer/369220.png","ImageObject",300,407,{"name":42,"@type":43},"Oliver","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why target miR-21 in lung cancer?","Question",{"text":63,"@type":64},"miR-21 is overexpressed in many cancers and activates carcinogenic processes, including PI3K/AKT signaling, partly by down-regulating PTEN and PDCD4.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was miR-21 knocked out in the study?",{"text":68,"@type":64},"CRISPR/Cas9 technology was used to knock out miR-21 in A549 lung cancer cells, generating miR-21 KO cells.",{"name":70,"@type":61,"acceptedAnswer":71},"What changes did miR-21 KO produce in A549 cells?",{"text":72,"@type":64},"miR-21 KO reduced proliferation, migration, and colony formation, increased PTEN and PDCD4 expression, and decreased the IC50 values for several lung-cancer chemotherapeutics.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369220,1790231676,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Article  \nExploring miR-21 Knock-Out Using CRISPR/Cas as a Treatment for Lung Cancer  \nPatricia Lara 1, Araceli Aguilar-González 2,3, Francisco Martín 2,4,5, Cristina Mesas 1,6, Javier Moreno 1 and Ana R. Rama 1,4,7, *  \nAcademic Editor: Sudheer Kumar Gara  \nReceived: 17 December 2024  \nRevised: 17 January 2025  \nAccepted: 20 January 2025  \nPublished: 24 January 2025  \nCitation: Lara, P.;  \nAguilar-González, A.;  \nMartín, F.; Mesas, C.; Moreno, J.; Rama, A.R.. Exploring miR-21 Knock-Out Using CRISPR/Casas a Treatment for Lung Cancer. Genes 2025, 16, 133 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)genes16020133  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Institute of Biopathology and Regenerative Medicine (IBIMER), Center of Biomedical Research (CIBM), University of Granada, 18100 Granada, Spain  \n2 GENYO, Centre for Genomics and Oncological Research: Pfizer, University of Granada, Andalusian Regional Government PTS Granada, 18016 Granada, Spain  \n3 Department of Medicinal & Organic Chemistry and Excellence Research Unit of “Chemistry Applied to Biomedicine and the Environment”, Faculty of Pharmacy, University of Granada, Campus de Cartuja, 18071 Granada, Spain  \n4 Instituto de Investigación Biosanitaria de Granada, ibs. GRANADA, 18014 Granada, Spain  \n5 Departamento de Bioquímica y Biología Molecular e Inmunología, Facultad de Medicina, Universidad de Granada, 18071 Granada, Spain  \n6 Department of Anatomy and Embryology, Faculty of Medicine, University of Granada, 18016 Granada, Spain  \n7 Department of Health Sciences, University of Jaén, 23071 Jaén, Spain  \n* Correspondence: arama@ujaen.es  \nAbstract: Background: Lung cancer is a leading cause of cancer-related deaths worldwide. Its high incidence and poor prognosis demonstrate the need to investigate new therapies. The PI3K/AKT pathway is activated in carcinogenic processes such as invasion, proliferation, and drug resistance. MiR-21 is a microRNA overexpressed in numerous types of cancer and which activates PI3K/AKT pathway by down-regulating its main targets, PTENand PDCD4 . CRISPR is a revolutionary gene-editing technology that allows genes to be deleted. The aim of this study was to use CRISPR/Cas9 technology as an option to reduce carcinogenic and drug resistance processes by eliminating miR-21 . Methods: CRISPR/Cas9 was used to knock out miR-21 (miR-21 KO) in A549 lung cancer cells and thus reverse the carcinogenic processes activated by miR-21 overexpression. Furthermore, the effect of miR-21 KO on drug resistance was studied, choosing the main chemotherapeutic agents used for the treatment of lung cancer: gemcitabine, carboplatin, paclitaxel, and oxaliplatin. Results: miR-21 KO A549 cells exhibited a reduction in proliferation, migration, and colony formation compared to A549 cells. In contrast, the expression of PTEN and PDCD4 increased in miR-21 KO A549 cells. Furthermore, miR-21 KO A549 cells showed a decrease in the IC50 of the drugs used for the treatment of lung cancer: gemcitabine, carboplatin, paclitaxel, and oxaliplatin. Conclusions: Based on these results, miR-21 knock-out using CRISPR/Cas could be a promising strategy for the treatment of lung cancer.  \nKeywords: miRNA; miR-21; CRISPR/Cas9; lung cancer; A549 cells  \n1. Introduction  \nLung cancer is the second of the most common and deadly types of cancer worldwide. It is considered the leading cause of cancer-related mortality in both women and men [1] . The 5-year survival rate from the diagnosis of the disease is much lower (17.4%) than those of other types of cancer, mainly due to its late diagnosis in advanced stages [2] . Specifically, 2.2 million new cases of lung can","cbCaiuQm4Kf9dVt2","https://ap.wps.com/l/cbCaiuQm4Kf9dVt2","pdf",1494473,12,"English","# Introduction\n# Methods\n# Results\n# Conclusions","[{\"question\":\"Why target miR-21 in lung cancer?\",\"answer\":\"miR-21 is overexpressed in many cancers and activates carcinogenic processes, including PI3K/AKT signaling, partly by down-regulating PTEN and PDCD4.\"},{\"question\":\"How was miR-21 knocked out in the study?\",\"answer\":\"CRISPR/Cas9 technology was used to knock out miR-21 in A549 lung cancer cells, generating miR-21 KO cells.\"},{\"question\":\"What changes did miR-21 KO produce in A549 cells?\",\"answer\":\"miR-21 KO reduced proliferation, migration, and colony formation, increased PTEN and PDCD4 expression, and decreased the IC50 values for several lung-cancer chemotherapeutics.\"}]","Exploring miR-21 Knock-Out Using CRISPR/Cas as a Treatment for Lung Cancer | PDF",1790181457,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6d1de4848c3840f4bee4e40e80319ae4.webp",983,1390,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/07689c62ed86c340cbfd867e97d05126.webp",982,1388,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/098fbf52e71a838a950c9e1eb5a5b541.webp",981,1387,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1710da590b4a6ccfe5d9ca746a0f261d.webp",980,1385]